Lucida Medical was invited to join the Edison Accelerator programme for its pioneering work in helping identify prostate cancer and its exceptional development team led by Prof Evis Sala and Dr Antony Rix, both highly experienced in artificial intelligence, or AI, medical technology.
Insulet will present new clinical outcomes data for preschool children with type 1 diabetes using the Omnipod 5 Automated Insulin Delivery System (Omnipod 5).
AN OPPORTUNITY FOR $800K IN SEED FUNDING
Medical device start-ups
The 2020 Vascular Challenge by MEDX Xelerator focuses on two domains of innovation: peripheral interventions (PI) and disruptive neurovascular technologies.
Monday, November 30, 2020
THE TWO ROUTES OF MEDX S’XELERATOR 2020 VASCULAR CHALLENGE
Technology: An early-stage company looking for a seed round of ~$800K operating in the field of peripheral interventions or neurovascular. MEDX is open to reviewing technologies that already implemented a prototype with proof of concept or are just an idea looking for feasibility testing. We are generally also open to ventures that are either formed as companies or not yet. The technology may be an established technology from another field redirected to peripheral interventions or neurovascular, an improvement over existing technologies or a new technology.
Unmet Clinical needs: Typically an MD or entrepreneur identifying a strong clinical need within the field of peripheral interventions & neurovascular without a solution.
About MEDX Xelerator
MEDX Xelerator is a leading MedTech incubator – a partnership of Boston Scientific, Sheba Medical Center and MEDX Ventures. Operating under the auspices of the Israel Innovation Authority, MEDX leverages the healthcare expertise and industry experience of its team with the industry leading insights of its partners to identify and nurture high impact medical ventures for the benefit of patients and health care professionals. MEDX’s portfolio companies all address major clinical needs with significant innovation in big markets and the incubator team works closely with the teams to consistently achieve outstanding clinical and business goals in capital efficient way. The incubation program is a 2-years program with $800K in seed funding and access to a strong network, of Key Opinion Leaders and supports all aspects of the ventures including business
development, multi-disciplinary R&D, IP consultation, marketing and PR services, accounting and administrative office services. All companies operate from the incubator office space -a vibrant environment of innovation and a company culture that supports focus and goal achievement. The incubator is open to innovation coming from
either Israel or international entrepreneurs, universities and hospitals.
Non-cardiac vascular diseases are a major cause of disability. Common vascular diseases include atherosclerosis, stroke, blood clots, peripheral artery disease, aneurysms, hypertension, and pulmonary embolisms. Vascular diseases can cause blocked or narrowed arteries and veins in the neck, arms, legs and abdomen (peripheral vessels in areas other than the heart). Peripheral vascular intervention procedures are used to open blocked arteries and veins.
Interventional radiologists use medical tools such as guidewires, catheters and ablation tools along with imaging modalities like fluoroscopy, ultrasound, computed tomography, and magnetic resonance imaging to repair blockages in the peripheral blood vessels.
Suggested Vascular Development Directions:
Create a disruptive and new technology for intravascular imaging
Novel solutions for deep venous disease (e.g., occlusions, incompetent valves) to treat chronic venous insufficiency
Make existing vascular disease procedures more effective or create new procedures
Chronic Total Occlusion (CTO) tools
Venous access devices
Smart guidewires (force sensing)
Vascular image processing
Neurovascular diseases are a leading cause of adult disabilities and death. Neurovascular diseases include abnormalities of the blood vessels supplying the brain and spine such as arteries narrowing and arteries weakening. Common neurovascular diseases are stroke, brain aneurysm, carotid stenosis, venous sinus thrombosis, cerebral cavernous malformation, intracranial vascular disease, and Moyamoya disease.
Suggested Neurovascular Development Directions:
Disruptive opportunities within the broader neurovascular space
Dr. Crane’s work to streamline operations positioned and prepared TeamHealth and its clinicians to face the COVID-19 pandemic. Under Dr. Crane’s leadership, TeamHealth was able to maintain high levels of clinical quality throughout the rapidly changing COVID environment.
Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).